Worldwide, stroke is a leading cause of death and disability. Recombinant tissue
plasminogen activator (rtPA) was approved a decade ago for the treatment of acute ischemic …

The discovery that brain tissue could potentially be salvaged from ischaemia due to stroke,
has led to major advances in the development of therapies for ischemic stroke. In this …

BACKGROUND: Quick administration of intravenous recombinant tissue plasminogen
activator (rt-PA) after stroke improved outcomes in previous trials. We aimed to analyse …

Objective To determine whether prespecified baseline magnetic resonance imaging (MRI)
profiles can identify stroke patients who have a robust clinical response after early …

Background Whether intravenous tissue plasminogen activator (alteplase) is effective
beyond 3 h after onset of acute ischaemic stroke is unclear. We aimed to test whether …

It is unknown whether collateral vessel status, as seen on computed tomography
angiography, can predict the fate of penumbral tissue identified on perfusion computed …

Background and Purpose—Hyperglycemia at the time of ischemic stroke is associated with
increased mortality and morbidity. Animal studies suggest that infarct expansion may be …

Background Intravenous thrombolysis with alteplase within a time window up to 4.5 h is the
only approved pharmacological treatment for acute ischemic stroke. We studied whether …

Background—The ability to quickly and efficiently identify the ischemic penumbra in the
acute stroke clinical setting is an important goal for stroke researchers and clinicians. Early …

Stroke is a leading cause of death and disability worldwide. Imaging plays a critical role in
evaluating patients suspected of acute stroke and transient ischemic attack, especially …